Signal active
Bio
Dr. Cheng of Morningside Technology Advisory LLC focuses on life science and technology investments. Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs.
Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi in the Genetics and Aging Unit of the Massachusetts General Hospital / Harvard Medical School. He has worked with many start ups and currently sits on the Board of Directors of Traversa Therapeutics and is a board observer to Argos Therapeutics.
Location
N/A
Social
Primary Organization
1986
163
53
33
51-100
Financial Services, Venture Capital, Finance, Biotechnology, Pharmaceutical, Product Research
Jobs history
3
Board Member
2022 - Current
Revolo Biotherapeutics
Non-Executive Board Director
Invalid date - Current
Big Health
Board Member
2020 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Isaac Cheng is the Investment Professional at Morningside Group, based in Asia. With a background in Financial Services, Isaac Cheng has a rich history of leadership and innovation. Isaac Cheng studied MD M.D. @ Tufts University School of Medicine. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
8
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Sep 21, 2020 | Revolo Biotherapeutics | Series B - Revolo Biotherapeutics | Morningside Venture Investments | 52.0M |
Jul 20, 2021 | Amylyx Pharmaceuticals | Series C - Amylyx Pharmaceuticals | Morningside Venture Investments | 135.0M |
Jan 19, 2022 | Big Health | Series C - Big Health | Morningside Venture Investments | 75.0M |
May 04, 2022 | - | Series C - Apnimed | Morningside Ventures | 62.5M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.